Hemostasis Today
NewsFeed
Headlines Hematology Health Medicine VTE ASH Plasma Donation
Wolfgang Miesbach: Key Open Questions and Clinical Paradoxes in ITP
Wolfgang Miesbach/LinkedIn; John Semple/Loop Frontiers
Apr 16, 2026, 08:47

Wolfgang Miesbach: Key Open Questions and Clinical Paradoxes in ITP

Wolfgang Miesbach, Professor of Medicine at Frankfurt University Hospital, shared a post on LinkedIn:

”Unanswered questions and paradoxes in ITP

Following his great talk on platelet kinetics and the Platelet Variability Index, John Semple also reminded us how many key questions in ITP remain open.

Why do platelet counts correlate so poorly with bleeding in many patients?

  • Is anti‑platelet antibody testing really necessary for diagnosis and management – and does antibody specificity dictate where platelets are destroyed (spleen vs liver) and how patients respond to therapy?
  • What is the role of complement, genetic factors and bone marrow changes (including megakaryocyte damage and mitophagy) in driving or sustaining the disease?
  • And what actually causes ‘refractoriness’ – persistent ITP despite multiple therapies?
  • On top of this, we face the ‘ITP paradox’: patients live with bleeding risk from thrombocytopenia, yet they are also at increased risk of arterial and venous thrombosis, influenced by patient‑related factors, ITP itself and treatments such as TPO‑RAs.”

Wolfgang Miesbach: Key Open Questions and Clinical Paradoxes in ITP

Stay updated with Hemostasis Today.

bleeding disorders Health Hematology Hemostasis Hemostasis News Hemostasis Today Immune thrombocytopenia ITP John Semple Medicine Platelet Variability Index TPO Wolfgang Miesbach
NewsFeed